Bio-Rad Laboratories (BIO) Scheduled to Post Quarterly Earnings on Tuesday

Bio-Rad Laboratories (NYSE:BIO) will post its quarterly earnings results after the market closes on Tuesday, May 7th. Analysts expect the company to announce earnings of $2.04 per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Bio-Rad Laboratories (NYSE:BIO) last announced its earnings results on Thursday, February 15th. The medical research company reported $3.10 EPS for the quarter, topping analysts’ consensus estimates of $2.93 by $0.17. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 23.86%. The company had revenue of $681.18 million for the quarter, compared to analysts’ expectations of $685.00 million. During the same period last year, the firm earned $3.31 EPS. Bio-Rad Laboratories’s revenue for the quarter was down 6.7% compared to the same quarter last year. On average, analysts expect Bio-Rad Laboratories to post $10 EPS for the current fiscal year and $11 EPS for the next fiscal year.

Bio-Rad Laboratories Stock Performance

Shares of BIO stock traded down $2.47 during trading hours on Tuesday, reaching $274.64. 5,101 shares of the company traded hands, compared to its average volume of 199,951. The firm has a 50-day moving average price of $323.67 and a 200 day moving average price of $316.47. Bio-Rad Laboratories has a 12-month low of $261.59 and a 12-month high of $473.50. The company has a quick ratio of 4.34, a current ratio of 5.83 and a debt-to-equity ratio of 0.14.

Insider Buying and Selling at Bio-Rad Laboratories

In other news, EVP Michael Crowley sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $336.00, for a total transaction of $1,008,000.00. Following the completion of the transaction, the executive vice president now owns 6,942 shares in the company, valued at $2,332,512. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 17.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Royal Bank of Canada reduced their price objective on shares of Bio-Rad Laboratories from $484.00 to $480.00 and set an “outperform” rating for the company in a research note on Friday, February 16th. StockNews.com upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday, April 25th. Citigroup cut Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and decreased their price target for the company from $400.00 to $365.00 in a report on Wednesday, April 3rd. Finally, UBS Group upped their price objective on Bio-Rad Laboratories from $395.00 to $420.00 and gave the stock a “buy” rating in a research note on Friday, February 16th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $468.00.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.